Skip to main content

Tirofiban Disease Interactions

There are 2 disease interactions with tirofiban.

Major

GpIIb/IIIa platelet inhibitors (applies to tirofiban) bleeding risks

Major Potential Hazard, High plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect, Cerebral Vascular Disorder, Hypertension, Brain/Intracranial Tumor

The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.

References

  1. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L (1987) "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med, 82, p. 703-13
  2. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ (1994) "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol, 74, p. 1166-70
  3. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP (1996) "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol, 78, p. 1161
  4. (2001) "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc
  5. Adgey AA (1998) "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J, 135, s43-55
  6. Kleiman NS (1997) "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol, 80, b29-33
  7. The IMPACT-II Investigators (1997) "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet, 349, p. 1422-8
  8. The RESTORE Investigators (1997) "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation, 96, p. 1445-53
  9. (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
View all 9 references
Major

Tirofiban (applies to tirofiban) renal dysfunction

Major Potential Hazard, High plausibility.

Tirofiban is primarily eliminated by the kidney. Approximately 65% of tirofiban is excreted in the urine, largely unchanged. The serum concentration of tirofiban is significantly increased (>50%) in patients with a creatinine clearance <30 mL/min (including hemodialysis patients). Therapy with tirofiban should be administered cautiously and initiated at a reduced dosage in patients with severe renal impairment. Clinical monitoring of renal function and bleeding activity is recommended. Tirofiban is removed by dialysis.

References

  1. (2001) "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc

Tirofiban drug interactions

There are 146 drug interactions with tirofiban.

Tirofiban alcohol/food interactions

There is 1 alcohol/food interaction with tirofiban.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer